MSD secures EC approval for Keytruda mixture remedy for ovarian most cancers
Merck (MSD) has acquired European Fee (EC) approval for Keytruda (pembrolizumab) along with paclitaxel, with or with out bevacizumab, as a remedy for programmed loss of life ligand 1 (PD-L1)-positive ovarian most cancers.
The approval within the European Union (EU) applies to adults with platinum-resistant epithelial ovarian, fallopian tube or main peritoneal carcinoma whose tumors are PD-L1 optimistic, with a mixed optimistic rating of a number of, and who’ve beforehand acquired one or two systemic remedy regimens.
Uncover B2B advertising and marketing that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra info
It additionally impacts Keytruda SC, recognized within the US as Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph).
The choice follows a optimistic opinion from the European Medicines Company’s Committee for Medicinal Merchandise for Human Use (CHMP) in February 2026.
The authorization is predicated on outcomes from the part III research KEYNOTE-B96, also referred to as ENGOT-ov65.
Within the research, Keytruda plus paclitaxel, with or with out bevacizumab, demonstrated a statistically vital and clinically significant enchancment in progression-free survival, the first endpoint, versus placebo plus paclitaxel, with or with out bevacizumab.
It additionally improved total survival, a key secondary endpoint, in sufferers with platinum-resistant relapsed ovarian most cancers whose tumors expressed PD-L1 with a mixed optimistic rating. [CPS] of no less than one.
Dr. Gursel Aktan, vp of world medical growth at Merck Analysis Laboratories, mentioned: “We’re proud to supply this Keytruda-based routine to eligible sufferers in Europe with PD-L1-positive platinum-resistant ovarian most cancers – giving this group entry to the area’s first PD-1 inhibitor remedy choice for this illness.
“This milestone marks actual progress for sufferers and advances our broader mission to broaden entry to efficient choices for girls’s cancers worldwide.”
The approval applies to all 27 EU member states, plus Norway, Iceland and Liechtenstein.
In February 2026, the US Meals and Drug Administration (FDA) permitted the identical routine within the US for a similar grownup affected person inhabitants.
